Table 2.

IC₅₀ or IG₅₀ (micromolar) of selected carbene gold(I) compounds against breast cancer cell lines.

Compounds	MCF7	MDA-MB-231	MDA-MB-468	HS-578T	BT-549	Ref
[(3,4,5-R1, R2, R3-phenyl)(1-(4-methoxy-5-R)-phenyl)-imidazol-2-yl]2Au]BF4	0.06 ± 0.01	nd	nd	nd	nd	[56] a
[{1-methyl-3-(1-phenyl-1-ol-methyl)-imidazol-2-yl}2gold[AgI2]	1 *	nd	nd	nd	nd	[57]
[1,3-dibenzyl-4,5-diphenyl-imidazol-2-yl-gold(I)]chloride	1.31 *	nd	1.39 *	2.40 *	1.66 *	[58]
[1,3-dimethylimidazol-2-yl-Au(but-3-yn-1-yl 2-(4-isobutylphenyl)propanoate)]	1.25 ± 0.05	1.97 ± 0.10	nd	nd	nd	[40]
[{1-benzyl-3-(but-3yn-1yl)-imidazol}-2yl-gold(I)]bromide	17.1 ± 0.4	nd	nd	nd	nd	[59]
[{1-methyl-3-butyl-imidazol}-2yl-gold(I)]PF6	1.49 ± 0.5	nd	nd	nd	nd	[60]
[1,3-diethyl-4-(4-bromophenyl)imidazol-2yl-gold]bromide	0.06 *	0.18 ± 0.01	nd	nd	nd	[42]
[(1-methyl-2-(phenyl)imidazo[1,5-a]pyridine-2-yl)2gold(I)]PF6	0.8 ± 0.28	nd	nd	nd	nd	[61]
[(C^Npz^C)(2,6-bis(4′-tert-butylphenyl)pyrazine-Au(III)-1,3-dimethylbenzimidazol-2-yl]	0.56 ± 0.02	nd	nd	nd	nd	[62]
[(C^Npz^C)(2,6-bis(4′-tert-butylphenyl)pyrazine)-Au(III)(1,3,7,9-tetramethylxanthin-8-yl)]	7.90 ± 0.13	nd	nd	nd	nd	[62]
[{1-[2-(diethylamino)ethyl]imidazolyl-2yl]2Au]NO3}	0.8 *	nd	nd	nd	nd	[63]
[bis(4-R*-imidazolyl)2Au]iodide	0.18 ± 0.02	nd	nd	nd	nd	[43] b
Cisplatin	21.2 ± 3.9	7.41	nd	nd	nd	[62]

* Statistical errors have not been reported. ^a R₁ = R₂ = R₃ methoxy, R₁ = R₂ ≠ R₃, where R₃ = Cl or Br; R = OH or (OPO₃)²⁻2Na⁺. ^b R* = H, Br, phenyl, 4-bromo-phenyl.